Cerebri:缩短急性缺血性卒中决策时间并提高指南依从性的网络应用
Cerebri应用组影像至决策中位时间显著缩短(6 vs 22分钟),总体指南依从性显著更高(96% vs 73.9%)。
要点
- Cerebri应用使影像至治疗决策中位时间从22分钟降至6分钟。
- Cerebri组总体指南依从性96%,对照组73.9%,校正后OR 11.6。
- 治疗性指南依从性两组差异未达统计学显著(100% vs 86.9%,P=0.062)。
核心结论
- Cerebri显著改善急性缺血性卒中超急性期决策速度与指南依从性。
- 该应用在非三级卒中中心亦展现可行性与有效性。
研究设计与样本
- 前瞻性、单中心、日历日随机试点研究,于意大利罗马Campus Bio-Medico大学医院急诊科开展。
- 研究期为2024年12月1日至2025年3月30日,共80个有效研究日。
- 按日随机分配至Cerebri组(提供临床决策支持加计时功能)或对照组(仅计时功能,无决策支持),由当日值班神经科医生使用应用。
主要发现
- Cerebri组影像至决策中位时间显著缩短(6 vs 22分钟;校正差值-18.8分钟[95%CI,-37.4至-3.5];P=0.009)。
- Cerebri组总体指南依从性显著更高(96% vs 73.9%;校正OR 11.6[95%CI,1.12-121.16];P=0.040)。
- 治疗性指南依从性Cerebri组100%、对照组86.9%,差异未达统计学显著(P=0.062)。
关键数值与推荐
- 主要结局为影像至决策时间(影像完成至治疗决策的时间,分钟)和欧洲卒中组织指南依从性。
- 指南依从性以依从病例百分比表示,分别评估诊断决策(适当影像模式)、治疗决策(适当治疗选择)和总体依从性(诊断与治疗域均依从)。
- 采用多变量线性与逻辑回归分析,校正年龄、美国国立卫生研究院卒中量表评分和血运重建治疗。
临床怎么用
- Cerebri可作为急性缺血性卒中超急性期临床决策支持工具,帮助缩短影像至治疗决策时间。
- 该应用有助于提高对欧洲卒中组织指南的总体依从性,尤其在非三级卒中中心具有推广潜力。
局限性
- 治疗性指南依从性差异未达统计学显著(P=0.062)。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Clinical decision support systems hold promise for improving adherence to guidelines and reducing decision-making time in acute ischemic stroke management. We developed a stroke-specific clinical decision support system smartphone app termed cerebri and assessed its efficacy in reducing imaging-to-decision time and enhancing guideline adherence in a real-world clinical setting. METHODS: We conducted a prospective, single-center, calendar-day-randomized pilot study at the Emergency Department of Campus Bio-Medico University Hospital in Rome, Italy, from December 1, 2024, to March 30, 2025 (80 effective study days). Eligible participants were adult patients (≥18 years) with suspected ischemic stroke presenting within 24 hours of symptom onset. Randomization occurred by day, assigning patients to either the cerebri group (app providing clinical decision support plus a timer function) or the control group (timer function only, without decision support). The app was used by the neurologist on-call that workday. Primary outcomes were imaging-to-decision time (imaging to decision time: the time from imaging completion to therapeutic decision, in minutes) and adherence to European Stroke Organization guidelines. Guideline adherence was expressed as the percentage of cases compliant, and assessed separately for diagnostic decisions (appropriate imaging modality), therapeutic decisions (appropriate treatment choice), and overall adherence (compliance with both diagnostic and therapeutic domains). Multivariable linear and logistic regression analyses adjusted for age, National Institutes of Health Stroke Scale, and revascularization therapies were performed. RESULTS: Fifty patients (mean age, 73.1±13.3 years; 64% female) were enrolled (25 cerebri, 25 control). Patients in the cerebri group had significantly reduced median imaging to decision time (6 versus 22 minutes; adjusted difference: -18.8 minutes [95% CI, -37.4 to -3.5]; P=0.009). Overall guideline adherence was significantly higher in the cerebri group (96% versus 73.9%; adjusted odds ratio, 11.6 [95% CI, 1.12-121.16]; P=0.040). Therapeutic guideline adherence was 100% in the cerebri group versus 86.9% in the control (P=0.062). CONCLUSIONS: Cerebri significantly improved decision-making speed and adherence to stroke guidelines in the hyperacute management of ischemic stroke. The app demonstrated feasibility and efficacy even in nontertiary stroke centers, suggesting its potential for broader implementation to enhance stroke care quality and equity.
引用
- Bonura A, Musotto G, Rossi SS, et al. Cerebri: A Web-App to Reduce Door-to-Treatment Decision Time and Improve Guideline Adherence in Acute Ischemic Stroke. Stroke. 2025. PMID: 41208703. doi:10.1161/STROKEAHA.125.052997
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。